Aortic Valve Disease Clinical Trial
Official title:
A Single Arm, Non-randomized, Multi-center Clinical Study of the SJM Masters HP 15mm Rotatable Mechanical Heart Valve as Aortic Valve Replacement Therapy
Verified date | February 2024 |
Source | Abbott Medical Devices |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This PAS is an observational, non-randomized, multi-center, single arm, clinical study to evaluate long term safety and effectiveness of the SJM™ Masters Series Hemodynamic Plus (HP) 15mm aortic mechanical heart valve (15 AHPJ-505) as a replacement device for pediatric patients with a diseased, damaged, or malfunctioning aortic valve.
Status | Active, not recruiting |
Enrollment | 20 |
Est. completion date | October 2028 |
Est. primary completion date | June 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Inclusion criteria for prospectively enrolled subjects - Subject's legal guardian must provide written informed consent prior to any clinical study related procedure. - Subject requires aortic valve replacement and is intended to be implanted with a 15mm SJM15 AHPJ-505 MHV as determined by the implanting physician in accordance with the Instructions for Use. - The legal guardian and site agree to follow the subject per the assessment schedule and complete all required assessments per this protocol for the duration of the clinical study. - Inclusion criteria for retrospectively enrolled subjects : In an effort to ensure data on all real-world use conditions are consistently collected and reported on, a subject is eligible to participate in this post-approval study if he/she meets all of the following inclusion criteria and meets no exclusion criterion. For those subjects with a previous implant attempt to be eligible for study participation, the following inclusion criteria must be met: - Echocardiography data at a time point greater than 90 days is available or may be acquired. - An implant was attempted with the 15mm MHV, where implant attempt is defined as the device physically contacting the subject's cardiac anatomy. - Either: - For living subjects who already received the 15mm MHV, the legal guardian signs the study informed consent for this protocol allowing access to all relevant historical medical information, and complete all required assessments according to this protocol from the time of consent going forward (if applicable). OR - For subjects who are deceased or explanted, an implantation with 15mm MHV was attempted and the subject's legal guardian provides written informed consent for retrospective data collection of patient and study valve related information through death or explant of the study device. Exclusion Criteria: - Exclusion criteria for prospectively enrolled subjects: Subject has a contraindication to anticoagulant/antiplatelet medication. - Exclusion criteria of retrospectively enrolled subjects: None |
Country | Name | City | State |
---|---|---|---|
Germany | Medizinische Hochschule Hannover | Hannover | |
Germany | Herzzentrum Leipzig GmbH | Leipzig | Saxony |
Germany | Deutsches Herzzentrum München des Freistaates Bayern | München | Bavaria |
Germany | Sana - Herzchirurgische Klinik Stuttgart GmbH | Stuttgart | Baden-Wurttemberg |
United States | Children's Healthcare of Atlanta | Atlanta | Georgia |
United States | Dell Children's Medical Center | Austin | Texas |
United States | Cincinnati Children's Hospital | Cincinnati | Ohio |
United States | Children's Medical Center Dallas | Dallas | Texas |
United States | University of Mississippi Medical Center | Jackson | Mississippi |
United States | Children's Hospital Los Angeles (USC) | Los Angeles | California |
United States | Valley Children's Hospital | Madera | California |
United States | Variety Children's Hospital | Miami | Florida |
United States | Sutter Medical Center, Sacramento | Sacramento | California |
Lead Sponsor | Collaborator |
---|---|
Abbott Medical Devices |
United States, Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of total serious valve-related adverse events | actuarial (Kaplan-Meier) rate of total serious valve-related adverse events experienced through 5 years post implant or until the valve is removed/replaced. Valve-related adverse events to be evaluated are:
Death; Endocarditis; Hemorrhage (whether or not due to anticoagulant/antiplatelet medication); Nonstructural dysfunction (including perivalvular leak, hemolysis, and hemolytic anemia); Reoperation (including valve explant, not due to anatomical growth of the subject); Structural valve deterioration; Thromboembolism Valvular thrombosis |
5 Years | |
Primary | Peak gradient as assessed by echocardiography | Peak gradient as assessed by echocardiography at 30 Days, 6 Months, 1 Year, 2 Year, 3 Year, 4 Year, 5 Year | Up to 5 years | |
Primary | Mean gradient as assessed by echocardiography | Mean gradient as assessed by echocardiography at 30 Days, 6 Months, 1 Year, 2 Year, 3 Year, 4 Year, 5 Year | Up to 5 years | |
Primary | Valvular regurgitation as assessed by echocardiography | Valvular regurgitation as assessed by echocardiography at 30 Days, 6 Months, 1 Year, 2 Year, 3 Year, 4 Year, 5 Year | Up to 5 years | |
Secondary | Number of all-cause deaths | 1 Year | ||
Secondary | Number of valve-related deaths | 1 Year | ||
Secondary | Number of reoperations or explants excluding replacement due to somatic growth | 1 Year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04149600 -
Identification of Genetic Causes of Calcific Aortic Valve Disease
|
||
Recruiting |
NCT06001489 -
The Effects of 360-degree Virtual Reality on Pre-procedural Anxiety in Patients Awaiting Elective Cardiac Surgery Involving a Sternotomy
|
N/A | |
Not yet recruiting |
NCT04430972 -
Immune Responsiveness and Outcome After Aortic Valve Surgery (Measure)
|
||
Completed |
NCT02467062 -
Implementation of Non-size Markers Derived From 4D Flow MRI of Patients With Aortic Disease.
|
N/A | |
Not yet recruiting |
NCT02221921 -
Safety and Efficacy Study of MicroPort's Transcatheter Aortic Valve and Delivery System for TAVI
|
N/A | |
Terminated |
NCT02128841 -
Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve.
|
Phase 2 | |
Active, not recruiting |
NCT01194362 -
A Study to Identify Differences in Gene Expression in Patients With Bicuspid and Tricuspid Valve Disease
|
||
Not yet recruiting |
NCT05975567 -
Deploying Novel Imaging Modalities Towards a Three-dimensional (3D) CARDIOvascular PATHology
|
||
Recruiting |
NCT06025149 -
The Study on the Use of "UniLine" Bioprosthesis in the Treatment of Isolated Aortic and Mitral Valve Diseases
|
||
Completed |
NCT05082337 -
The SAVVY Guidewire in Transcatheter Aortic Valve Replacement Procedures
|
N/A | |
Completed |
NCT05193760 -
Robustness Check of Placement and Measurement Algorithms for Blood Flow Measurement on Common Carotid Artery
|
||
Not yet recruiting |
NCT05941455 -
A Prospective Multicenter Pivotal Study to Evaluate Safety and Effectiveness of Venus-Neo Surgical Aortic Valve
|
N/A | |
Active, not recruiting |
NCT04950192 -
Philips Intracardiac Echocardiography (ICE) Clinical Registry
|
||
Completed |
NCT04073875 -
18F-GP1 PET-CT to Detect Bioprosthetic Aortic Valve Thrombosis
|
||
Recruiting |
NCT03121053 -
Preventing contrAst Induced Nephropathy After TranscathEter Aortic Valve Replacement
|
Phase 4 | |
Completed |
NCT02000544 -
Clinical Evaluation of a Modular Extracorporeal Circulation Circuit
|
N/A | |
Completed |
NCT02981004 -
PAR I - Patient-to-Annulus Relation I
|
||
Completed |
NCT02688153 -
EDWARDS INTUITY Valve System CADENCE Study
|
N/A | |
Recruiting |
NCT06126367 -
Assessment of Lipoprotein(a) and Endogenous Fibrinolysis in Atherosclerotic Cardiovascular Disease/Aortic Valve Disease
|
||
Active, not recruiting |
NCT05082454 -
Post Market Clinical Follow-Up Study in Patients Treated With the On-X Ascending Aortic Prosthesis (AAP)
|